Zimbabwe

KEY RESULTS - HIV

 

920,000 people living with HIV currently on ART (2016)

Source: UNDP

People living with HIV on antiretroviral therapy (aged 15-64 in 2015-16)

Source: ZIMPHIA

14,000 HIV infections averted through prevention of mother-to-child transmission in 2015

Source: UNAIDS

Reducing the cost of HIV treatment

Price negotiations between UNDP and suppliers have  achieved a landmark cost for ARVs of less than US$100 per patient per year for the one-pill combination of the three HIV medicines known as TLE (Tenofovir, Lamivudine and Efavirenz). Because of this UNDP was able to purchase 4.8 million packs of medicines for US$ 40 million for Zimbabwe – resulting in savings of over US$ 11 million compared to previous orders. With these savings, an additional 110,000 people in Zimbabwe can now be put on HIV treatment meaning the Ministry of Health and Child Care is now providing HIV treatment to a total of 920,000 people. This number is set to reach 1 million people in 2017 with further support from the Global Fund, PEPFAR, DFID and UNDP.

KEY RESULTS - MALARIA

4.4 million insecticide treated bed nets distributed

Source: UNDP

Coverage of bed nets (2015)

Source: World Health Organization

463,000 cases of Malaria treated

Source: UNDP

KEY RESULTS - TB

 

48,100 new smear positive TB cases detected and treated

Source: UNDP

   

Treatment success rate for new TB cases (2014)

Source: World Health Organization

   

72% of HIV positive TB patients on ART in (2015)

Source: World Health Organization

TB incidence

Source: World Health Organization

MORTALITY RATES

 

Maternal mortality

Source: World Health Organization

Infant mortality

Source: World Health Organization

Project Summary

UNDP has managed the implementation of Global Fund HIV, TB and Malaria grants in Zimbabwe since 2009. The AIDS epidemic in Zimbabwe is in decline with prevalence amongst males and females decreasing by 30% and 20% respectively between 2005 and 2015. Despite this, the prevalence of HIV remains among the highest in the world with 1.2 million people living with HIV (14.6% of people aged 15-64). Prevalence is higher amongst women, with the difference being most marked for younger age groups 20-34. Prevalence is also particularly high amongst sex workers. The HIV grant focuses on treatment and prevention, voluntary counselling and testing, and prevention of mother-to-child transmission (PMTCT). Malaria is a major public health problem and efforts are focused on enabling people to identify early symptoms, building the capacity of health workers, and procuring rapid diagnostic tests. Despite decreases in both incidence and prevalence of TB in Zimbabwe, in 2015 it was one of the fourteen countries classed by WHO as high burden for TB, multi-drug resistant TB and HIV/TB co-infection. TB is also one of the most common causes of death in Zimbabwe. The UNDP-managed Global Fund investments have been instrumental in saving many lives. The number of people on antiretroviral therapy (ART) rose from 360,000 in 2010 to 920,000 in 2016. This resulted in 87% of people living with HIV being on ART in 2015-6. Additionally, 4.4 million insecticide treated nets have been distributed to protect families from malaria and 48,100 new smear-positive TB cases have been detected and treated. Better health is central to human well-being and makes an important contribution to social and economic progress, as healthy populations live longer and are more productive. Life expectancy in Zimbabwe, which had declined since the 1980s to 41 years in 2003, subsequently increased to 61 years in 2015.

PORTFOLIO OVERVIEW

 

 

Disease Component

HIV

Grant

ZIM-H-UNDP

Phase

Period 1

Amount

                        $611,375,034

Rating

 

 

 

Overall Grant Rating

 

 

  Exceeding expectations

 

  Meeting expectations

 

  Adequate

 

  Inadequate but potential demonstrated

 

  Unacceptable

 

  No rating available